[The synthetic peptide preparation dalargin in the treatment of peptic ulcer]. 1987

V G Smagin, and V A Vinogradov, and S A Bulgakov, and E P Propisnova, and M I Titov

The paper is concerned with the results of clinical assessment of a new peptide drug dalargin in therapy of duodenal peptic ulcer. Assessment of the efficacy of dalargin was compared to that of tagamet and placebo using double "blind" control. A total of 180 males with exacerbation of duodenal ulcer were examined, of them 90 received dalargin only, 70 received tagamet and 20 persons participated in an experiment based on a method of double "blind" control. An average period of duodenal ulcer healing in the patients on dalargin therapy was 21.4 +/- 1.2 days, and by the 28th day complete cicatrization was observed in 87.5% of the patients. In tagamet therapy an average period of cicatrization was 23.7 +/- 1.8 days, by the 28th day ulcer healing was observed in 87.3%. With placebo ulcer healing by the 4th week was observed in 30% of the examinees, in dalargin therapy in 80%. A conclusion was made of high efficacy of dalargin for therapy of peptic ulcer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004381 Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM. Curling's Ulcer,Curling Ulcer,Curlings Ulcer,Duodenal Ulcers,Ulcer, Curling,Ulcer, Duodenal,Ulcers, Duodenal
D004743 Enkephalin, Leucine One of the endogenous pentapeptides with morphine-like activity. It differs from MET-ENKEPHALIN in the LEUCINE at position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN. Leucine Enkephalin,5-Leucine Enkephalin,Leu(5)-Enkephalin,Leu-Enkephalin,5 Leucine Enkephalin,Enkephalin, 5-Leucine,Leu Enkephalin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

V G Smagin, and V A Vinogradov, and S A Bulgakov, and E P Propisnova, and M I Titov
March 1990, Khirurgiia,
V G Smagin, and V A Vinogradov, and S A Bulgakov, and E P Propisnova, and M I Titov
January 1986, Biulleten' Vsesoiuznogo kardiologicheskogo nauchnogo tsentra AMN SSSR,
V G Smagin, and V A Vinogradov, and S A Bulgakov, and E P Propisnova, and M I Titov
January 1991, Vrachebnoe delo,
V G Smagin, and V A Vinogradov, and S A Bulgakov, and E P Propisnova, and M I Titov
January 1953, La Riforma medica,
V G Smagin, and V A Vinogradov, and S A Bulgakov, and E P Propisnova, and M I Titov
January 1988, Klinicheskaia meditsina,
V G Smagin, and V A Vinogradov, and S A Bulgakov, and E P Propisnova, and M I Titov
February 1992, Likars'ka sprava,
V G Smagin, and V A Vinogradov, and S A Bulgakov, and E P Propisnova, and M I Titov
February 1960, Svenska lakartidningen,
V G Smagin, and V A Vinogradov, and S A Bulgakov, and E P Propisnova, and M I Titov
January 1985, Biulleten' Vsesoiuznogo kardiologicheskogo nauchnogo tsentra AMN SSSR,
V G Smagin, and V A Vinogradov, and S A Bulgakov, and E P Propisnova, and M I Titov
January 1986, Biulleten' Vsesoiuznogo kardiologicheskogo nauchnogo tsentra AMN SSSR,
V G Smagin, and V A Vinogradov, and S A Bulgakov, and E P Propisnova, and M I Titov
January 1986, Biulleten' Vsesoiuznogo kardiologicheskogo nauchnogo tsentra AMN SSSR,
Copied contents to your clipboard!